Pfizer (PFE +1.34%) is emerging as a potential long-term investment opportunity despite recent stock struggles, with a nearly 30% decline over the past five years. Investors are concerned about the company’s growth prospects, particularly with looming patent expirations for key drugs like Eliquis and Ibrance, which could lead to a revenue loss of up to $18 billion by 2030. However, CEO Albert Bourla has outlined a strategy to counteract these declines through acquisitions and internal development, aiming to boost revenues by $25 billion.
The company’s aggressive approach includes notable acquisitions, such as the $43 billion purchase of Seagen, which enhances its oncology portfolio, and a $10 billion investment in Metsera, positioning Pfizer in the anti-obesity market. With over 100 drug candidates in its pipeline and a strong profit margin, Pfizer is taking steps to secure future growth.
For market professionals, Pfizer’s current valuation—trading at just nine times expected future profits—suggests it may be undervalued. While risks remain, the potential for significant returns makes it an intriguing option for long-term investors willing to weather short-term volatility.
Source: fool.com